KINGSTON, Jamaica— The Jamaica Tourist Board (JTB) and the Jamaica Travel Channel (JTC) have agreed on a collaboration to stream destination video content across several digital platforms through a redesigned Jamaica Travel Channel. Already boasting more than 250,000 monthly online viewers, the revamped channel showcases some of Jamaica’s best accommodations, breathtaking experiences, and stunning vistas. The channel will offer options on where to stay and what to do while visiting Jamaica and will be featured on the homepage of JTB’s popular VisitJamaica.com website with links to the JamaicaTravelChannel.com platform along with a presence on YouTube and other social media platforms. JTC said the move aligns with the growing trend toward online media consumption while influencing travellers on where and how best to explore and experience the island. “This relationship is in alignment with our mandate to increase awareness and bring heads to bed for the destination. We welcome this addition to promote Jamaica to wider audiences that will increase our appeal as the ideal destination to visit,” said Minister of Tourism Edmund Bartlett. Originally launched in 2015 as Jamaica’s first and only visitor in-room TV channel, the JTC already enjoys a robust presence in almost all hotel rooms islandwide, where it is viewed by tens of thousands of visitors to the island daily. JTC added that it is leading the Caribbean as an independent tourism video platform boasting expanded online streaming capability, an already successful print magazine and a vibrant social media following of more than 40,000. Kimani Robinson, founder and director of JTC emphasised the impact of this new venture. “We currently receive hundreds of emails monthly from tourists thanking us for our platform which acts as a guide for them while on island. Streaming the Jamaica Travel Channel online significantly boosts our visibility before travelers even arrive in Jamaica. With our unmatched showcase of hotels, excursions, and cultural experiences, the JTC is now Jamaica’s premiere social video influence,” said Robinson. The JTC video content features a mix of lifestyle, music, and off-the-beaten-path experiences that creates an immersive and visually stunning representation of the island’s unique offerings. In addition to providing valuable content for prospective travellers, the online channel may also serve as a resource for travel agents worldwide, helping them recommend Jamaica’s best experiences to their clients, JTC said Popular brands such as Dunn’s River Falls, RIU Hotel, Couples Hotel, Jakes Hotel, Island Routes, Mystic Mountain, The Artisan Village in Falmouth, are among some of the destinations featured in the channel’s online stream. “This initiative will expand our audience reach. The Jamaica Travel Channel has become a dedicated global platform, and this effort will effectively support JTB’s strategy to leverage media and technology in promoting Jamaica to a worldwide audience,” said Donovan White, director of tourism.
ECU CB Shavon Revel Jr. declares for NFL draft
HERZLIYA, Israel and CALGARY, Alberta , Dec. 12, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and an owner of a proprietary intellectual property portfolio, is pleased to share its annual "State of Research and Development" update for 2024. This year, the Company achieved significant milestones in advancing research and development for its drug delivery platforms as well as its intellectual property portfolio. During 2024, Innocan achieved significant milestones in both scientific and regulatory domains. Preclinical studies of its liposome-cannabidiol technology (LPT-CBD( demonstrated high CBD bioavailability, along with long-lasting pain relief and improved well-being in various animal models. Building on this compelling data, the Company secured agreement from the United States Food and Drug Administration (FDA) on the preclinical and Phase 1 clinical development plan to advance LPT-CBD as a treatment for chronic pain in humans. Additionally, the FDA acknowledged LPT-CBD's development under the 505(b)(2) regulatory pathway, which provides Innocan with an accelerated route to patent utilization and commercialization. On the veterinary front, LPT-CBD's innovation was recognized by the FDA's Center for Veterinary Medicine (CVM), which granted Innocan a fee waiver for 2024 and issued a number that identifies an Investigational New Animal Drug (INAD). This designation allows Innocan to facilitate correspondence and data exchange with the CVM to support the development of LPT-CBD as a new veterinary drug. Iris Bincovich, CEO of Innocan Pharma, commented: "In 2024, we not only met but surpassed our FDA-related goals, achieving regulatory milestones ahead of schedule. With the FDA 505(b)(2) regulatory pathway meeting behind us, these advancements position us to accelerate our development in 2025, bringing us closer to delivering innovative pain management solutions for both human and veterinary applications." The 505(b)(2) FDA regulatory pathway offers a streamlined approach for developing a long-acting injectable cannabinoid using a liposomal drug delivery platform to treat chronic pain. By leveraging existing pre-clinical data from approved products, this pathway is expected to significantly shorten both development time and cost. This pathway facilitates innovative formulations like liposomal delivery, by allowing for modifications to dosage forms, administration routes, or drug combinations, all while adhering to stringent safety and efficacy standards. This approach is expected to accelerate market entry and address unmet medical needs in chronic pain management. Company ' s Update on its Activity in Research and Development and FDA interactions On February 26, 2024 , the Company announced the latest findings from the Company's pharmacokinetic study of its liposome CBD platform ("LPT-CBD") in rabbits. In agreement with studies conducted in other animals (mice, dogs, goats, and sheep) this study resulted in prolonged exposure of CBD obtained following a single subcutaneous LPT-CBD injection. This data along with data obtained from other organisms injected with the Company's liposomal CBD, consistently demonstrates that a detectable CBD level could be maintained for weeks following a single injection. On March 5, 2024 , the Company announced the results of a recent tissue distribution study of its liposome CBD platform (LPT-CBD), that indicated the potential of LPT-CBD to support a new therapeutic venue for neurological disorders. In this study, CBD was found to be in the brains of both mice and rabbits weeks after LPT-CBD was subcutaneously injected to them. LPT technology provides a long presence of CBD in the blood enabling CBD to pass the blood brain barrier (BBB) and deliver long brain exposure. On April 22, 2024 , the Company announced that it had submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for LPT-CBD. Innocan's Pre-IND meeting request letter to the FDA represents a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. The objective of the Pre-IND meeting is to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an investigational new drug ("IND") program in the United States . On May 9, 2024 , the Company announced the successful pre-clinical treatment of amputee female donkey with a liposomal-CBD injection. Miri, a-7-year-old female donkey, had undergone amputation of her right front limb, leaving the weight burden primarily on her left front limb. This led to an inflammatory disease affecting the soft tissue that connects the foot bone to the hoof, seemingly causing extreme pain and limited mobility. In a compassionate act, Miri was administered a liposomal-CBD injection. The effect was immediate as Miri regained her ability to walk and move as she had before her inflammatory disease developed. On May 21, 2024 , the Company announced significant advancements in the regulatory process for its LPT-CBD, which provides an innovative solution in non-opioid pain management. The FDA granted Innocan an INAD number and approved an initial meeting with the Company to discuss the strategic path forward. The meeting with the FDA was on July 31, 2024 , where Innocan presented its preclinical results and proposed clinical development plan. The meeting is key to launching human clinical trials for the LPT-CBD injectable drug, developed to provide a novel treatment option for chronic pain. On June 11, 2024 , the Company announced the success and conclusion of a preliminary safety evaluation of Innocan's single injection and sustained-release LPT-CBD conducted on minipigs. Recognized by the FDA as an excellent model for toxicology, minipigs are small breeds of miniature domestic pigs which share strong similarities with humans in crucial aspects such as drug metabolism, skin structure, genetics, and physiological mechanisms. In this preliminary safety study, minipigs received a single subcutaneous injection of LPT-CBD and were closely monitored for pharmacokinetics and basic safety parameters over one month. The animals all exhibited good drug tolerance and did not manifest any drug-related adverse reactions. On July 2, 2024 , the Company announced that it engaged the Past President of the Eastern Pain Association, Dr. William K. Schmidt , to support its LPT-CBD submission process to the FDA for chronic pain. His extensive expertise in pain-related clinical development and regulatory affairs will strongly contribute to Innocan's team during the LPT-CBD submission process with the FDA. Dr. Schmidt brings over 25 years of pharmaceutical industry clinical trial experience, specializing in analgesic and narcotic antagonist drug development. On July 26, 2024 , the Company announced that the CVM) granted the Company a sponsor fee waiver and assigned an INAD number for its LPT-CBD product. This represented a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug. The Company further announced that following the assessment of LPT-CBD's scientific package, the CVM recognized Innocan's contribution to pursuing innovative animal drug products and technology and granted the Company a sponsor fee waiver for fiscal year 2024. Over the past year, repeated administration of LPT-CBD in dogs and other animals demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application. On September 3, 2024 , the Company announced that it received a positive response from the FDA following Innocan's successful pre-IND Type B meeting with the FDA held in July, for its lead drug product LPT-CBD. The FDA has agreed to LPT-CBD's submission under the 505(b)(2) New Drug Application (NDA) by establishing a scientific bridge to the reference listed drug. The 505(b)(2) abbreviated pathway, as it is often described, typically enables a faster route to patent utilization and commercial approval. This pathway is a significant milestone for Innocan, as it may pave the way for a streamlined and accelerated FDA approval process for LPT-CBD, while allowing Innocan to advance its patent protected innovation. In addition, Innocan has reached an alignment with the FDA on both its non-clinical development plan and the clinical study design for LPT-CBD's proposed IND filing for a Phase I clinical study. On October 9, 2024 , The Company announced that Dr. Joseph V. Pergolizzi, Jr. , M.D., a member of the Company's Scientific Advisory Board, was recognized among the top 2% most cited scientists in the world in a new list published by Stanford University . This achievement underscores Dr. Pergolizzi's long-term contribution to medical science and his influential role in shaping global healthcare practices. Dr. Pergolizzi was appointed to be part of Innocan's Scientific Advisory Board in September 2023 . His role focuses on promoting pharmaceutical human product R&D and supporting the Company's planned FDA filing for new medications. His expertise in pain management, critical care medicine, and regulatory processes are key in advancing the issuer's pharmaceutical developments. On October 11, 2024 , the Company announced promising results from a multi-year compassionate therapy using repeated LPT-CBD injections for pain relief in dogs with naturally occurring osteoarthritis. The therapy consistently demonstrated pain reduction and improved mobility, with effects lasting for several weeks after each injection as expected. These results further demonstrate that LPT-CBD can be a viable treatment option for managing chronic pain and enhancing the quality of life in animals. In two ongoing cases, dogs suffering from osteoarthritis who were treated with LPT-CBD after failing to respond to non-steroidal anti-inflammatory drugs (NSAIDs) and oral CBD, showed noticeable pain relief, substantially improved mobility and increased well-being which was clearly noticeable. Both dogs remained on LPT-CBD treatment for 2 and 2.5 years, respectively after their owners reported significant improvement in quality of life, receiving the treatment in addition to other conventional treatments. About Innocan Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd. which focuses on advanced, targeted online sales. www.innocanpharma.com For further information, please contact: Iris Bincovich, CEO +1-516-210-4025 +972-54-3012842 +44 203 769 9377 info@innocanpharma.com NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Cautionary note regarding forward-looking information Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry and potential for patent utilization and commercialization is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedar.com . Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. Logo - https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpgTrump's picks for key positions in his second administration
PROVIDENCE, R.I. (AP) — Aaron Cooley's 17 points helped Brown defeat Stony Brook 77-54 on Wednesday. Cooley also contributed five rebounds for the Bears (4-3). AJ Lesburt Jr. scored 16 points, going 6 of 10 (4 for 8 from 3-point range). Landon Lewis shot 5 of 8 from the field to finish with 12 points, while adding eight rebounds. Joseph Octave finished with 24 points, seven rebounds and two steals for the Seawolves (2-5). Stony Brook also got 17 points and three steals from Ben Wight. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Larry Hogan came to Washington with a very simple message on Thursday: America is tired of you. All of you. The former governor of Maryland came up short in his bid to be the first Republican senator from Maryland in decades in November. This week, he gave his first remarks since the election at No Labels, the bipartisan organization he co-chaired before his Senate bid. The Independent was provided with a copy of his prepared remarks, in which the governor touted his ability to significantly outperform the president-elect in the state of Maryland despite his defeat; Hogan also noted that he did so better than any Republican in a statewide election across the country. In the end, an 11.7-point gap separated him from Angela Alsobrooks , the victorious senator-elect. Hogan attributed his success to a rejection of the divisive, dysfunctional status quo — in both parties. “We overperformed the top of the ticket by 17 points — more than any other statewide race in America,” Hogan said, according to the prepared remarks. “We created a model, and forged a path for all those who believe in civility, bipartisan compromise, and common sense for the common good.” His campaign, the governor added, “proved that politics can be more than just red vs. blue.” Hogan’s ability to win over Democrat voters was key to his two successful gubernatorial runs, though it could not quite convince Marylanders that he wouldn’t reliably caucus with MAGA Republicans in the next Senate. Despite his arguments throughout the campaign that he would serve as an independent voice and vote in the Senate, he couldn’t overcome the leftward bent of his state’s politics. The remarks were received with a standing ovation from the group he joined just over three years prior to launching his bid for Senate. While serving at the organization, he was beset by overtures from moderate Republicans in his party to run for president. That path never materialized as Donald Trump reasserted his dominance over the party and trampled over critics and allies alike to complete a near-total sweep of the GOP primaries. Republicans on the Hill leaned on the popular two-term governor to run for Senate as well, given that he was seen as likely the only Republican with a serious shot of winning a seat in Maryland, where a retiring Democratic senator left Republicans a key opening. Hogan told The Independent earlier this year that he eventually decided to run — despite having said thet he did not want to be in the Senate — given his overwhelming frustration with the collapse of negotations around a bipartisan border security and immigration bill the chamber considered in the spring. He took aim at the sentiment which killed that bill again on Thursday, telling No Labels: “Both parties have been doing a lot more subtracting and dividing lately.” “Durable solutions don’t come from ramming policies through on party-line votes,” Hogan said. “They come from honest negotiations, compromise, and a shared sense of responsiblity to serve the people.” Maryland’s former governor gave no signs of any future plans in his remarks, however. Republicans like Mitt Romney who have expressed an interest in remain a part of the GOP’s post-Trump future are taking somewhat of a holding pattern ahead of the president-elect’s second term. Many remain unsure that there will be a post-Trump future for the party, or whether instead the dominance of Trumpism will carry on after 2028.‘The Day of the Jackal’ Finale Recap: A Thrilling Conclusion & Vision for Season 2
On 16 December 2024, the European Union (EU) adopted its 15th package of sanctions against Russia in response to its ongoing aggression toward Ukraine. The new measures target key sectors of Russia’s military-industrial complex, including the “shadow fleet” and companies that support this complex. In a significant development, the EU has imposed fully-fledged sanctions – a travel ban, an asset freeze and prohibitions to making economic resources available – for the first time on third-country actors, including Chinese companies, that are implicated in the supply of electronic components and drones used in the conflict. These actions reflect the EU’s determination to extend its pressure on those facilitating Russia’s military activities. Additionally, the package designates 54 individuals and 30 entities. Among those designated are high-ranking executives in Russia’s energy sector, and other political figures. The sanctions also target defence companies, shipping firms responsible for transporting Russian oil, and a civilian airline aiding Russian military logistics. This broadening of sanctions underscores the EU’s strategy to disrupt the logistical and financial support structures enabling Russia’s military operations. In addition to targeting key individuals and entities, the EU has expanded trade restrictions to include 32 new entities involved in supplying dual-use goods and technologies to the Russian military. These entities, based in countries such as China, India, Iran, Serbia and the UAE, are reported to have participated in circumventing practices or to have provided critical materials used in Russian missile and drone production. The sanctions are designed to prevent a further reinforcement of Russia’s military machinery by cutting off access to essential components and technologies. Further, the EU Council is expanding the list of vessels subject to a port access ban and a prohibition on a wide range of maritime transport-related services. This action aims to address non-EU tankers associated with Putin’s shadow fleet, which evade the oil price cap mechanism, support Russia’s energy sector, transport military equipment for Russia, or facilitate the movement of stolen Ukrainian grain. Today, 52 vessels from third countries were added to the list, bringing the total number of designated vessels to 79. To safeguard European businesses, the EU has also implemented protective measures, including the prohibition of recognising or enforcing rulings from Russian courts that seek to impose unjust economic sanctions on EU operators. Additionally, the EU has introduced mechanisms that facilitate the release of certain frozen assets held by EU central securities depositories, enabling them to meet their legal obligations to clients. These measures are aimed at ensuring that EU businesses can operate without fear of being unfairly targeted by Russian legal actions. Recognising the challenges that businesses face in maintaining operations in Russia, the EU has extended the deadlines for European companies to exit the Russian market in an orderly manner. These exceptional derogations are granted on a case-by-case basis, mitigating the impact on business operations and facilitating a smoother exit from Russia’s increasingly restrictive and uncertain environment. In reaffirming its condemnation of the conflict, the council has emphasised that the EU is ready to adopt additional measures. This 15th package of sanctions underscores the EU’s commitment to applying sustained economic and political pressure on Russia while intensifying its multifaceted support for Ukraine – support delivered on humanitarian grounds, as well as militarily, politically and economically. These new sanctions are said to be just a preview of the broader restrictive measures to be taken next year.Disclaimer: This is paid sponsored content in the Morning Blend. All opinions and views are of the advertiser and do not reflect the same of KGUN-TV. Learn more at eeeveterans.org
President-elect Donald Trump has filled the key posts for his second term in office, prioritizing loyalty to him after he felt bruised and hampered by internal squabbling during his first term. Some of his choices could face difficult confirmation fights in the Senate, even with Republicans in control, and one candidate has already withdrawn from consideration. Former Florida Rep. Matt Gaetz was Trump's initial pick for attorney general, but he ultimately withdrew following scrutiny over a federal sex trafficking investigation he was embroiled in. Here's a look at Trump's choices: Trump would turn a former critic into an ally as the nation's top diplomat. Rubio , 53, is a noted hawk on China, Cuba and Iran, and was a finalist to be Trump's running mate before the slot went to JD Vance. Rubio is vice chairman of the Senate Intelligence Committee and a member of the Senate Foreign Relations Committee. His selection punctuates the hard pivot Rubio has made with Trump, whom the senator once called a “con man" during his own unsuccessful campaign for the 2016 Republican presidential nomination. Their relationship improved dramatically while Trump was in the White House. Hegseth , 44, was a co-host of Fox News Channel’s “Fox and Friends Weekend” and had been a contributor with the network since 2014. He developed a friendship with Trump, who made regular appearances on the show. Hegseth served in the Army National Guard from 2002 to 2021, deploying to Iraq in 2005 and Afghanistan in 2011 and earning two Bronze Stars. He lacks senior military and national security experience and would oversee global crises ranging from Europe to the Middle East. A woman told police that she was sexually assaulted in 2017 by Hegseth after he took her phone, blocked the door to a California hotel room and refused to let her leave, according to a detailed investigative report recently made public. Hegseth told police at the time that the encounter had been consensual and has denied any wrongdoing. Bessent , 62, is a former money manager for George Soros , a big Democratic donor, and an advocate for deficit reduction . He founded the hedge fund Key Square Capital Management after having worked on and off for Soros Fund Management since 1991. If confirmed by the Senate, Bessent would be the nation’s first openly gay treasury secretary. He told Bloomberg in August that he decided to join Trump’s campaign in part to attack the mounting U.S. national debt. That would include slashing government programs and other spending. Gabbard, 43, is a former Democratic House member from Hawaii who has been accused of echoing Russian propaganda. She unsuccessfully sought the party’s 2020 presidential nomination and left the party in 2022. Gabbard endorsed Trump in August and campaigned often with him. Gabbard has served in the Army National Guard for more than two decades and deployed to Iraq and Kuwait. If confirmed she would come to the role as an outsider compared to her predecessor. The current director, Avril Haines, spent several years in top national security and intelligence positions. Bondi , 59, was Florida's first female attorney general, serving between 2011 and 2019. She was on Trump’s legal team during his first impeachment trial in 2020. Considered a loyalist , Bondi also has served with the America First Policy Institute, a Trump-allied group that has helped lay the groundwork for his future administration. Bondi was among a group of Republicans who showed up to support Trump at his hush-money criminal trial in New York that ended in May with a conviction on 34 felony counts. A fierce defender of Trump, she also frequently appeared on Fox News and has been critical of the criminal cases against him. The Republican U.S. House member narrowly lost her reelection bid on Nov. 5 but had received strong backing from union members in her district. As a potential labor secretary, Chavez-DeRemer would oversee the department's workforce and budget and put forth priorities that affect workers’ wages, health and safety, ability to unionize, and employer’s rights to fire employers, among other responsibilities. Chavez-DeRemer is one of a few House Republicans to endorse the “Protecting the Right to Organize” or PRO Act that would allow more workers to conduct organizing campaigns and penalize companies that violate workers’ rights. The act would also weaken “right-to-work” laws in more than half the states. Lutnick heads the brokerage and investment bank Cantor Fitzgerald and is a cryptocurrency enthusiast. He is co-chair of Trump's transition operation, charged along with Linda McMahon, a former wrestling executive who previously led Trump’s Small Business Administration, with helping the president-elect fill key jobs in his second administration. As secretary, Lutnick would play a key role in carrying out Trump's plans to raise and enforce tariffs. He would oversee a sprawling Cabinet department whose oversight ranges from funding new computer chip factories and imposing trade restrictions to releasing economic data and monitoring the weather. Noem is a well-known conservative who used her two terms as South Dakota's governor to vault to a prominent position in Republican politics. During the COVID-19 pandemic, Noem did not order restrictions like other states, instead declaring South Dakota “open for business.” More recently, Noem faced sharp criticism for writing in her memoir about shooting and killing her dog. She is set to lead a department crucial to the president-elect’s hardline immigration agenda as well as other missions. Homeland Security oversees natural disaster response, the U.S. Secret Service and Transportation Security Administration agents who work at airports. Ratcliffe , a former U.S. House member from Texas, was director of national intelligence during the final year and a half of Trump’s first term. He led U.S. government’s spy agencies during the coronavirus pandemic. If confirmed, Ratcliffe will have held the highest intelligence positions in the U.S. Kennedy , 70, ran for president as a Democrat, then as an independent before he dropped out and then endorsed Trump . He's the son of Democratic icon Robert F. Kennedy, who was assassinated in 1968 during his own presidential campaign. Kennedy's nomination alarmed people who are concerned about his record of spreading unfounded fears about vaccines . For example, he has long advanced the debunked idea that vaccines cause autism. Rollins , 52, is president and CEO of the America First Policy Institute, a group helping to lay the groundwork for Trump's second administration. She is a Texas attorney who was Trump's domestic policy adviser and director of his office of American innovation during his first term. Rollins previously was an aide to former Texas Gov. Rick Perry , who also served in Trump's first term. Rollins also ran the Texas Public Policy Foundation. Duffy is a former House member from Wisconsin who was one of Trump's most visible defenders on cable news. Duffy served in the House for nearly nine years , sitting on the Financial Services Committee and chairing the subcommittee on insurance and housing. He left Congress in 2019 for a TV career and has been the host of “The Bottom Line” on Fox Business. Before entering politics, Duffy was a reality TV star on MTV, where he met his wife, “Fox and Friends Weekend” co-host Rachel Campos-Duffy. They have nine children. Collins is a former Republican congressman from Georgia who gained recognition for defending Trump during his first impeachment trial. Trump was impeached for urging Ukraine to investigate Joe Biden in 2019 during the Democratic presidential campaign, but was acquitted by the Senate. Collins also served in the armed forces himself. He is a chaplain in the United States Air Force Reserve Command. The North Dakota governor , 68, is a former Republican presidential primary contender who endorsed Trump after he dropped out of the running. Burgum then became a serious contender to be Trump’s vice presidential choice in part because of his executive experience and business savvy. He also has close ties to deep-pocketed energy industry CEOs. Trump said Burgum would chair a new National Energy Council and have a seat on the National Security Council, which would be a first for the Interior secretary. A campaign donor and CEO of Denver-based Liberty Energy, Wright is a vocal advocate of oil and gas development, including fracking — a key pillar of Trump’s quest to achieve U.S. “energy dominance” in the global market. He also has been one of the industry’s loudest voices against efforts to fight climate change. Wright said the climate movement around the world is “collapsing under its own weight.” The Energy Department is responsible for advancing energy, environmental and nuclear security of the United States. McMahon, a billionaire professional wrestling mogul , would make a return appearance in a second Trump administration. She led the Small Business Administration from 2017 to 2019 in Trump’s first term and twice ran unsuccessfully in Connecticut as a Republican candidate for the U.S. Senate. She served on the Connecticut Board of Education for a year starting in 2009 and has spent years on the board of trustees for Sacred Heart University. She has expressed support for charter schools and school choice. Zeldin does not appear to have any experience in environmental issues, but is a longtime supporter of the former president. The 44-year-old former U.S. House member from New York wrote on X , “We will restore US energy dominance, revitalize our auto industry to bring back American jobs, and make the US the global leader of AI" and "we will do so while protecting access to clean air and water.” Trump often attacked the Biden administration’s promotion of electric vehicles, and incorrectly referred to a tax credit for EV purchases as a government mandate. Trump also often said his administration would “drill, baby, drill,” referring to his support for expanded petroleum exploration. Turner is a former NFL player and White House aide. He ran the White House Opportunity and Revitalization Council during Trump’s first term in office. Trump, in a statement, credited Turner, the highest-ranking Black person he’s yet selected for his administration, with “helping to lead an Unprecedented Effort that Transformed our Country’s most distressed communities.” Greer is a partner at King & Spalding, a Washington law firm. If confirmed by the Senate, he would be responsible for negotiating directly with foreign governments on trade deals and disputes, as well as memberships in international trade bodies such as the World Trade Organization. He previously was chief of staff to Robert Lighthizer, who was the trade representative in Trump's first term. Wiles , 67, was a senior adviser to Trump’s 2024 presidential campaign and its de facto manager. She has a background in Florida politics , helping Ron DeSantis win his first race for Florida governor. Six years later, she was key to Trump’s defeat of him in the 2024 Republican primary. Wiles’ hire was Trump’s first major decision as president-elect and one that could be a defining test of his incoming administration considering her close relationship with him. Wiles is said to have earned Trump’s trust in part by guiding what was the most disciplined of Trump’s three presidential campaigns. Waltz is a three-term Republican congressman from east-central Florida. A former Army Green Beret , he served multiple tours in Afghanistan and worked in the Pentagon as a policy adviser when Donald Rumsfeld and Robert Gates were defense chiefs. He is considered hawkish on China, and called for a U.S. boycott of the 2022 Winter Olympics in Beijing due to its involvement in the origin of COVID-19 and its mistreatment of the minority Muslim Uighur population. Hassett, 62, is a major advocate of tax cuts who was chairman of the Council of Economic Advisers in the first Trump term. In the new role as chairman of the National Economic Council, Trump said Hassett will play an important role in helping American families recover from inflation as well as in renewing and improving tax cuts Trump enacted in 2017, many of which are set to expire after 2025. Homan, 62, has been tasked with Trump’s top priority of carrying out the largest deportation operation in the nation’s history. He led the U.S. Immigration and Customs Enforcement in Trump's first administration. Democrats have criticized Homan for defending Trump’s “zero tolerance” policy on border crossings in the first term, which led to the separation of thousands of parents and children seeking asylum at the border. Vought, 48, held the position during Trump’s first presidency. He the founded the Center for Renewing America, a think tank that describes its mission as “renew a consensus of America as a nation under God.” Vought also was closely involved with Project 2025 , a conservative blueprint for Trump’s second term that Trump tried to distance himself from during the campaign. Miller, an immigration hardliner , was a vocal spokesperson during the presidential campaign for Trump’s priority of mass deportations. The 39-year-old was a senior adviser during Trump’s first term. Miller has been a central figure in some of Trump’s policy decisions, notably his move to separate thousands of immigrant families. Trump argued throughout the campaign that the nation’s economic, national security and social priorities could be met by deporting people living illegally in the U.S. Scavino was an adviser in all three of the president-elect's campaigns and was described by the transition team as one of “Trump’s longest serving and most trusted aides." He will be deputy chief of staff and assistant to the president. Scavino previously ran Trump’s social media profile in the White House. Blair was political director for Trump’s 2024 campaign and for the Republican National Committee. He will be deputy chief of staff for legislative, political and public affairs and an assistant to the president. Blair was key to Trump’s economic messaging during his winning White House comeback campaign. Budowich is a veteran Trump campaign aide who launched and directed Make America Great Again, Inc., a super PAC that supported Trump’s 2024 campaign. He will be deputy chief of staff for communications and personnel and assistant to the president. Leavitt , 27, was Trump's campaign press secretary and currently a spokesperson for his transition. She would be the youngest White House press secretary in history. Leavitt worked in the White House press office during Trump's first term. In 2022, she ran for Congress in New Hampshire, winning a 10-way Republican primary before losing to Democratic Rep. Chris Pappas. McGinley was Cabinet secretary during Trump's first administration and was outside legal counsel for the Republican National Committee's election integrity effort during the 2024 campaign. The 67-year-old Witkoff is the president-elect's golf partner and they were golfing at Trump's club in West Palm Beach, Florida, on Sept. 15, when the former president was the target of a second attempted assassination. Trump also named Witkoff co-chair, with former Georgia Sen. Kelly Loeffler, of his inaugural committee. Kellogg , 80, is a highly decorated retired three-star general and one of the architects of a staunchly conservative policy book that lays out an “America First” national security agenda for Trump's second term. He has long been Trump’s top adviser on defense issues and served as national security adviser to Vice President Mike Pence . Kellogg also was chief of staff of the National Security Council under Trump and stepped in as an acting national security adviser for Trump after Michael Flynn resigned the post. Huckabee is a staunch defender of Israel and his intended nomination comes as Trump has promised to align U.S. foreign policy more closely with Israel's interests. Huckabee, who ran unsuccessfully for the Republican presidential nomination in 2008 and 2016, has been a popular figure among evangelical Christian conservatives, many of whom support Israel due to Old Testament writings that Jews are God’s chosen people and that Israel is their rightful homeland. Huckabee has rejected a Palestinian homeland in territory occupied by Israel. His daughter, Sarah Huckabee Sanders, served as White House press secretary in Trump's first term. Stefanik, 40, is a U.S. representative from New York and one of Trump's staunchest defenders dating to his first impeachment trial. She was elected chair of the House Republican Conference in 2021, the third-highest position in House leadership, after then-Rep. Liz Cheney was removed from the post after she publicly criticized Trump for falsely claiming he won the 2020 election. Stefanik’s questioning of university presidents over antisemitism on their campuses helped lead to two of those presidents resigning, further raising her national profile. A former acting attorney general during Trump's first administration and tight end on the University of Iowa football team, Whitaker , 55, has a background in law enforcement but not in foreign policy. A fierce Trump localist, Whitaker, is also a former U.S. attorney in Iowa and served as acting attorney general between November 2018 and February 2019 without Senate confirmation, until William Barr was confirmed for the role. That was when special counsel Robert Mueller’s investigation into Russian election interference was drawing to a close. Whitaker also faced questions about his past business dealings, including his ties to an invention-promotion company that was accused of misleading consumers. A Republican congressman from Michigan who served from 1993 to 2011, Hoekstra was ambassador to the Netherlands during Trump's first term. Oz , 64, is a former heart surgeon who hosted “The Dr. Oz Show,” a long-running daytime TV talk show. He ran unsuccessfully for the U.S. Senate as the Republican nominee in 2022 and is an outspoken supporter of Trump, who endorsed Oz’s bid for elected office. Makary is a Johns Hopkins surgeon and author who argued against pandemic lockdowns. He routinely appeared on Fox News during the COVID-19 pandemic and wrote opinion articles questioning masks for children. He cast doubt on vaccine mandates but supported vaccines generally. Makary also cast doubt on whether booster shots worked, which was against federal recommendations on the vaccine. Nesheiwat is a general practitioner who serves as medical director for CityMD, a network of urgent care centers in New York and New Jersey. She has been a contributor on Fox News. Weldon is a former Florida congressman who recently ran for a Florida state legislative seat and lost; Trump backed Weldon’s opponent. In Congress, Weldon weighed in on one of the nation’s most heated debates of the 1990s over quality of life and a right-to-die and whether Terri Schiavo, who was in a persistent vegetative after cardiac arrest, state should have been allowed to have her feeding tube removed. He sided with the parents who did not want it removed. Bhattacharya , 56, is a critic of pandemic lockdowns and vaccine mandates. As head of the NIH, the leading medical research agency in the United States, Trump said Bhattacharya would work with Kennedy Jr. to direct U.S. medical research and make important discoveries that will improve health and save lives. Bhattacharya is professor at Stanford University School of Medicine and was one of three authors of the Great Barrington Declaration, an October 2020 open letter maintaining that lockdowns during the COVID-19 pandemic were causing irreparable harm. Gaetz, 42, withdrew from consideration to become the top law enforcement officer of the United States amid fallout over a federal sex trafficking investigation that cast doubt on his ability to be confirmed by the Senate. In choosing Gaetz, Trump had passed over more established lawyers whose names had been floated as possible contenders for the job. Gaetz resigned from Congress after Trump announced him on Nov. 13. The House Ethics Committee has been investigating an allegation that he paid for sex with a 17-year-old. Gaetz has denied wrongdoing. Associated Press writers Colleen Long, Zeke Miller, Farnoush Amiri, Lolita C. Baldor, Jill Colvin, Matthew Daly, Edith M. Lederer, Adriana Gomez Licon, Lisa Mascaro, Chris Megerian, Michelle L. Price, Will Weissert and Darlene Superville contributed to this report.Erdoğan receives Blinken for talks on post-Assad Syria
HERZLIYA, Israel and CALGARY, Alberta , Dec. 12, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF ) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and an owner of a proprietary intellectual property portfolio, is pleased to share its annual "State of Research and Development" update for 2024. This year, the Company achieved significant milestones in advancing research and development for its drug delivery platforms as well as its intellectual property portfolio. During 2024, Innocan achieved significant milestones in both scientific and regulatory domains. Preclinical studies of its liposome-cannabidiol technology (LPT - CBD ( demonstrated high CBD bioavailability, along with long-lasting pain relief and improved well-being in various animal models. Building on this compelling data, the Company secured agreement from the United States Food and Drug Administration (FDA) on the preclinical and Phase 1 clinical development plan to advance LPT-CBD as a treatment for chronic pain in humans. Additionally, the FDA acknowledged LPT-CBD's development under the 505(b)(2) regulatory pathway, which provides Innocan with an accelerated route to patent utilization and commercialization. On the veterinary front, LPT-CBD's innovation was recognized by the FDA's Center for Veterinary Medicine (CVM), which granted Innocan a fee waiver for 2024 and issued a number that identifies an Investigational New Animal Drug (INAD). This designation allows Innocan to facilitate correspondence and data exchange with the CVM to support the development of LPT-CBD as a new veterinary drug. Iris Bincovich, CEO of Innocan Pharma, commented: "In 2024, we not only met but surpassed our FDA-related goals, achieving regulatory milestones ahead of schedule. With the FDA 505(b)(2) regulatory pathway meeting behind us, these advancements position us to accelerate our development in 2025, bringing us closer to delivering innovative pain management solutions for both human and veterinary applications." The 505(b)(2) FDA regulatory pathway offers a streamlined approach for developing a long-acting injectable cannabinoid using a liposomal drug delivery platform to treat chronic pain. By leveraging existing pre-clinical data from approved products, this pathway is expected to significantly shorten both development time and cost. This pathway facilitates innovative formulations like liposomal delivery, by allowing for modifications to dosage forms, administration routes, or drug combinations, all while adhering to stringent safety and efficacy standards. This approach is expected to accelerate market entry and address unmet medical needs in chronic pain management. Company ' s Update on its Activity in Research and Development and FDA interactions On February 26, 2024 , the Company announced the latest findings from the Company's pharmacokinetic study of its liposome CBD platform ("LPT-CBD") in rabbits. In agreement with studies conducted in other animals (mice, dogs, goats, and sheep) this study resulted in prolonged exposure of CBD obtained following a single subcutaneous LPT-CBD injection. This data along with data obtained from other organisms injected with the Company's liposomal CBD, consistently demonstrates that a detectable CBD level could be maintained for weeks following a single injection. On March 5, 2024 , the Company announced the results of a recent tissue distribution study of its liposome CBD platform (LPT-CBD), that indicated the potential of LPT-CBD to support a new therapeutic venue for neurological disorders. In this study, CBD was found to be in the brains of both mice and rabbits weeks after LPT-CBD was subcutaneously injected to them. LPT technology provides a long presence of CBD in the blood enabling CBD to pass the blood brain barrier (BBB) and deliver long brain exposure. On April 22, 2024 , the Company announced that it had submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for LPT-CBD. Innocan's Pre-IND meeting request letter to the FDA represents a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. The objective of the Pre-IND meeting is to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an investigational new drug ("IND") program in the United States . On May 9, 2024 , the Company announced the successful pre-clinical treatment of amputee female donkey with a liposomal-CBD injection. Miri, a-7-year-old female donkey, had undergone amputation of her right front limb, leaving the weight burden primarily on her left front limb. This led to an inflammatory disease affecting the soft tissue that connects the foot bone to the hoof, seemingly causing extreme pain and limited mobility. In a compassionate act, Miri was administered a liposomal-CBD injection. The effect was immediate as Miri regained her ability to walk and move as she had before her inflammatory disease developed. On May 21, 2024 , the Company announced significant advancements in the regulatory process for its LPT - CBD, which provides an innovative solution in non-opioid pain management. The FDA granted Innocan an INAD number and approved an initial meeting with the Company to discuss the strategic path forward. The meeting with the FDA was on July 31, 2024 , where Innocan presented its preclinical results and proposed clinical development plan. The meeting is key to launching human clinical trials for the LPT-CBD injectable drug, developed to provide a novel treatment option for chronic pain. On June 11, 2024 , the Company announced the success and conclusion of a preliminary safety evaluation of Innocan's single injection and sustained-release LPT-CBD conducted on minipigs. Recognized by the FDA as an excellent model for toxicology, minipigs are small breeds of miniature domestic pigs which share strong similarities with humans in crucial aspects such as drug metabolism, skin structure, genetics, and physiological mechanisms. In this preliminary safety study, minipigs received a single subcutaneous injection of LPT-CBD and were closely monitored for pharmacokinetics and basic safety parameters over one month. The animals all exhibited good drug tolerance and did not manifest any drug-related adverse reactions. On July 2, 2024 , the Company announced that it engaged the Past President of the Eastern Pain Association, Dr. William K. Schmidt , to support its LPT-CBD submission process to the FDA for chronic pain. His extensive expertise in pain-related clinical development and regulatory affairs will strongly contribute to Innocan's team during the LPT-CBD submission process with the FDA. Dr. Schmidt brings over 25 years of pharmaceutical industry clinical trial experience, specializing in analgesic and narcotic antagonist drug development. On July 26, 2024 , the Company announced that the CVM) granted the Company a sponsor fee waiver and assigned an INAD number for its LPT-CBD product. This represented a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug. The Company further announced that following the assessment of LPT-CBD's scientific package, the CVM recognized Innocan's contribution to pursuing innovative animal drug products and technology and granted the Company a sponsor fee waiver for fiscal year 2024. Over the past year, repeated administration of LPT-CBD in dogs and other animals demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application. On September 3, 2024 , the Company announced that it received a positive response from the FDA following Innocan's successful pre-IND Type B meeting with the FDA held in July, for its lead drug product LPT-CBD. The FDA has agreed to LPT-CBD's submission under the 505(b)(2) New Drug Application (NDA) by establishing a scientific bridge to the reference listed drug. The 505(b)(2) abbreviated pathway, as it is often described, typically enables a faster route to patent utilization and commercial approval. This pathway is a significant milestone for Innocan, as it may pave the way for a streamlined and accelerated FDA approval process for LPT-CBD, while allowing Innocan to advance its patent protected innovation. In addition, Innocan has reached an alignment with the FDA on both its non-clinical development plan and the clinical study design for LPT-CBD's proposed IND filing for a Phase I clinical study. On October 9, 2024 , The Company announced that Dr. Joseph V. Pergolizzi, Jr. , M.D., a member of the Company's Scientific Advisory Board, was recognized among the top 2% most cited scientists in the world in a new list published by Stanford University . This achievement underscores Dr. Pergolizzi's long-term contribution to medical science and his influential role in shaping global healthcare practices. Dr. Pergolizzi was appointed to be part of Innocan's Scientific Advisory Board in September 2023 . His role focuses on promoting pharmaceutical human product R&D and supporting the Company's planned FDA filing for new medications. His expertise in pain management, critical care medicine, and regulatory processes are key in advancing the issuer's pharmaceutical developments. On October 11, 2024 , the Company announced promising results from a multi-year compassionate therapy using repeated LPT-CBD injections for pain relief in dogs with naturally occurring osteoarthritis. The therapy consistently demonstrated pain reduction and improved mobility, with effects lasting for several weeks after each injection as expected. These results further demonstrate that LPT-CBD can be a viable treatment option for managing chronic pain and enhancing the quality of life in animals. In two ongoing cases, dogs suffering from osteoarthritis who were treated with LPT-CBD after failing to respond to non-steroidal anti-inflammatory drugs (NSAIDs) and oral CBD, showed noticeable pain relief, substantially improved mobility and increased well-being which was clearly noticeable. Both dogs remained on LPT-CBD treatment for 2 and 2.5 years, respectively after their owners reported significant improvement in quality of life, receiving the treatment in addition to other conventional treatments. About Innocan Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd. which focuses on advanced, targeted online sales. www.innocanpharma.com For further information, please contact: Iris Bincovich, CEO +1-516-210-4025 +972-54-3012842 +44 203 769 9377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Cautionary note regarding forward-looking information Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry and potential for patent utilization and commercialization is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedar.com . Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. Logo - https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg SOURCE Innocan Pharma CorporationWe've seen many examples recently of positive changes in both America's political and cultural landscapes. While we spill a lot of ink at Twitchy mocking or criticizing all of the horrible things that leftists do, we also love to celebrate the political and cultural wins from conservatives. At Christmas time, what better win could we get than seeing a real Nativity scene on display and reading of Scripture at the United States Capitol for the first time in history? If you are like this writer, you might be surprised that this was the first time this has happened, but it seems to be true. While we can't correct those ghosts of Christmases past, we can at least take joy in our Christmas present and have hope for our Christmases yet to come. 🚨New: A Nativity Scene will be displayed at the US Capitol for the First Time in American History pic.twitter.com/H9GbiR1ddZ There is a slight error in the tweet above, as the ceremony already took place earlier this week. The faith-based media site The Heartlander had the full story : A Nativity display along with prayer, Christmas carols, and a Scripture reading of the birth of Jesus was all part of an event held for the first time on the southeastern steps of the U.S. Capitol. Celebrated on Tuesday on the House of Representatives side of the Capitol, the event represents 'a significant victory for religious freedom and the First Amendment,' Rev. Patrick Mahoney, director of the Washington, D.C.-based Christian Defense Coalition, said in a press statement. 'This event has ended and won the war on Christmas in the public square,' Mahoney proclaimed. 'For if Christmas can be celebrated and displayed in the most powerful public square in America, it can be celebrated publicly everywhere.' The article goes on to recount how Mahoney was arrested in 2021 for trying to hold a similar event at the Capitol on Good Friday. But a 2024 ruling from James Boasberg, Chief Judge of the United States District for the District of Columbia said that the Capitol steps constituted the public square and that peaceful demonstrations could be held there. On December 10, Mahoney and others celebrated the ruling with a crèche, Scripture readings, and Christmas carols. The news was greeted with a few negative reactions on Twitter. This is absurd and should be taken to court. The first amendment guarantees I as a Jewish person don’t have to see a nativity scene displayed in a government building. https://t.co/46zPE5f4zq The First Amendment says no such thing. Moreover, the court says that, as a Jewish person, you can also have an event celebrating Jewish holidays on the Capitol steps. Some people also seemed to misunderstand that it was the federal government putting on the display, which it was not (but there would be nothing wrong with that either). Despite a few objections, though, the reactions were overwhelmingly positive. This is also a significant victory for religious freedom and the 1st Amendment https://t.co/0Kk0WS0BRS I can’t believe this wasn’t done before...praise God! As we noted above, that surprised us as well. pic.twitter.com/tSfZKsLrbj This is actually the best thing I’ve read in weeks!!!! Absolutely love this!!!! MAGA 🇺🇸🙏🏻 This is awesome. https://t.co/ailE3w5vP4 We think so too. We're winning https://t.co/VHYo9v2vGB The winds have definitely shifted. We can just feel it. Love seeing the impact of the Shift... God ain’t play’n around! 💪 https://t.co/UVlPKEbKXt There is a crèche in front of the county courthouse in my township and the ACLU knows better. This used to not be breaking news but normalcy. https://t.co/F3kR9GOeFB That's a fair point, but we are happy to celebrate a return to normalcy. BASED! https://t.co/ODqABxzJTp God bless and protect these United States of America 🙏🇺🇲 https://t.co/vs2LMSuS1v We can say Amen to that. “For unto you is born this day in the city of David a Saviour, which is Christ the Lord.” Luke 2:11 https://t.co/HvcJzOhAbu It's nice when we can all remember the reason for the season. On the grand scale of political events, this may be a blip, but it feels like an important one. As it's been said about so many positive current events... we're healing. https://t.co/BRVc1Ai8b7 It certainly appears that we are. And that's one more thing to be grateful for this Christmas.
Major poll puts Ireland’s lead parties near neck-and-neckPlan A works perfectly for West Virginia in upset of No. 3 Gonzaga
NorthWestern Energy to Supply Power for Butte, Montana Data Center Atlas Power Group